BridgeBio attracts takeover interest from pharma companies - Bloomberg News

March 24 (Reuters) - Gene therapy company BridgeBio Pharma Inc is attracting takeover interest from some large pharmaceutical firms, Bloomberg News reported on Friday, citing people familiar with the matter.

Shares of the California-based company were up nearly 13% at $16.82 in after-market trade. It has a market capitalization of $2.18 billion, according to Refinitiv data.

Talks of a takeover are ongoing and there is no certainty they will result in a transaction, the report said, adding that BridgeBio may decide to remain independent longer to benefit from the results of upcoming drug trials.

The company, which did not immediately respond to a Reuters request for comment, develops treatments for genetic diseases and cancers. (Reporting by Raghav Mahobe in Bengaluru; Editing by Devika Syamnath)